Infectious complications in chronic lymphoid malignancy.

被引:12
作者
Egerer G. [1 ]
Hensel M. [1 ]
Ho A.D. [1 ]
机构
[1] Department of Internal Medicine V, University of Heidelberg, Hospitalstrasse 3, Heidelberg
关键词
Chronic Lymphocytic Leukemia; Herpes Zoster; Fludarabine; Main Side Effect; Main Drug Interaction;
D O I
10.1007/s11864-001-0037-1
中图分类号
学科分类号
摘要
Taking steps to minimize, prevent, and treat infection in patients with chronic lymphoid malignancies, especially chronic lymphocytic leukemia, has always been a challenge. As more patients with these diseases live longer and lead productive lives upon successful initial treatment, strategies for preventing infections have become more important. Distinguishing patients at low risk for infection from those at high risk is a crucial but challenging issue. Unfortunately, there are hardly any data on the use of prophylactic antibiotics for patients with chronic lymphoid malignancy (CLL). If patients cannot be enrolled in a clinical trial, antibiotics with co-trimoxazole should be administered when steroids are warranted. They should also be administered in patients who have had a documented infection early in the treatment course and during neutropenia. Viral infections remain another controversial issue in patients with CLL receiving treatment, especially a purine analogue. Very low CD4 counts (less than 50 cells/mL) might predict for reactivation for herpes zoster. Outside of depleted CD4 counts, there are no other means of identifying a high-risk group. Based on limited data, it would be reasonable to administer herpes zoster prophylaxis to patients with CD4 counts that are severely depleted or to patients with a prior episode of zoster. Controversial issues still remain regarding immunoglobulin treatment, specifically cost, scarcity of the product, and adequate dose, which has not yet been established. We would consider intravenous immunoglobulin (Ig) replacement in patients with marked hypogammaglobulinemia (IgG less than 400 mg/dL) with more than two recent severe infections [1]. Lower Ig doses (240 mg/kg) have been shown to be equivalent to higher ones in this trial [1].
引用
收藏
页码:237 / 244
页数:7
相关论文
共 38 条
  • [1] Chapel H(1994)Immunoglobulin replacement in patients with chronic lymphocytic leukaemia: a comparison of two dose regimens Br J Haematol 88 209-212
  • [2] Dicato M(1990)Prognostic significance of immune function parameters in patients with chronic lymphocytic leukemia Eur J Haematol 44 39-44
  • [3] Gamm H(1992)Infections and serum IgG levels in patients with chronic lymphocytic leukemia Eur J Haematol 48 266-270
  • [4] Apostopoulos A(1984)Complement deficiency states and infection: epidemiology, pathogenesis and consequences of neisserial and other infections in immune deficiency Medicine (Baltimore) 63 243-273
  • [5] Simeonidis A(1998)The infectious complications of chronic lymphocytic leukemia Semin Oncol 25 98-106
  • [6] Zoumbos N(1986)Splenectomy for hematological cytopenias in patients with malignant lymphomas Lancet 2 250-253
  • [7] Itälä M(1994)Infections in chronic lymphocytic leukemia: risk factors and impact on survival and treatment Leuk Lymphoma 13 203-214
  • [8] Helenius H(1983)Severe pneumococcal infection in patients with neoplastic disease Cancer 51 1546-1550
  • [9] Nikoskelaien J(1998)Infections in patients with chronic lymphocytic leukemia treated with Fludarabine Ann Intern Med 129 559-566
  • [10] Ross SC(1993)Results of fludarabine and prednisone therapy in 264 patients with chronic lymphocytic leukemia with multivariate analysis-derived prognostic model for response to treatment Blood 82 1695-1700